Akeso, Summit cancer drug confirms lung cancer survival benefit
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
Search fresh public links, source activity, and ready-to-use post angles for Cancer-Specific Survival.
Fresh curated links around cancer-specific survival are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
A new data cut of a trial pitting ivonescimab, a bispecific antibody, against Merck’s Keytruda showed the new drug helped people live longer.
A Second Cancer Has Touched More Than 2.5 Million US Survivors, Study Finds More than 2.5 million people living in the United States after a cancer diagnosis have developed at leas...
Researchers in China have built and validated a statistical survival calculator for young patients with upper tract urothelial carcinoma using SEER registry data.
Like millions of people, Pope Leo XIV was diagnosed with lung cancer. This disease, though still serious, has also been transformed from one of daunting odds to a surmountable affl...
Early-onset colorectal cancer with liver-only metastases can have significant differences in biology from late-onset malignancies.A study of nearly 1,700 individuals from Australia...
For patients who undergo curative-intent surgery for hepatocellular carcinoma, the operation itself is only half the battle. Even when surgeons remove all visible tumor tissue, the...
It's one of the cruelest ironies in health and medicine. Pediatric sarcomas are among the rarest yet most aggressive forms of childhood cancer and some of the hardest to cure. Wher...
A short course of immunotherapy before surgery may offer remarkably durable protection for some patients with stage two or three bowel cancer. In the NEOPRISM-CRC trial, 32 patient...
Cancer survivors face a paradox that has long puzzled oncologists and public health researchers alike. Although they belong to one of the highest-risk groups for developing new pri...
Early intervention may mitigate elevated risk for cancer-specific mortality observed among people with pre-existing depression, according to retrospective findings.Individuals with...
By: Jennifer Larson From.oncologynurseadvisor.com More targeted education about survivorship care plans (SCPs) ensures cancer survivors understand the purpose of SCPs and their own...
Patients treated with gotistobart lived for a median 18.5 months, compared with 10 months for those given the standard-of-care chemotherapy.
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.